UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

~~under~~October 26, ~~the~~2017 ~~Securities Exchange Act of 1934~~

October 13, 2017

Lombard Medical, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Commission File Number 001-36402

N/A

(Translation of Registrant’s Name into English)

Cayman Islands

3841

Not applicable

(State or Other Jurisdiction of

Incorporation or Organization)

(Primary Standard Industrial

Classification Code Number)

(I.R.S. Employer Identification

Number)

Lombard Medical House

4 Trident Park

Didcot

Oxfordshire OX11 7HJ

+44-1235-750849

(Address, Including ZIP Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ ___

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ ___

~~Entry~~Notice ~~Into~~of Delisting or Failure to Satisfy a ~~Material~~Continued ~~Definitive~~Listing ~~Agreements~~Rule or Standard; Transfer of Listing.

On October 1326, 2017, the Board of Directors of Lombard Medical Inc., Inc. (the “Company”) ~~entered~~made ~~into a third amendment (~~the ~~“Amendment”)~~determination to ~~its~~delist ~~loan~~the ~~and security~~Company’s ~~agreement~~common ~~dated~~shares ~~as of April 24, 2015, as amended by the First Amendment to its Loan Agreement dated as of July 30, 2015, and the Second Amendment to Loan and Security Agreement dated as of May 31, 2017~~ (~~altogether,~~ the “~~Loan Agreement~~Common Shares”) byfrom ~~and~~the ~~among~~Nasdaq ~~Oxford~~Capital ~~Finance~~Market ~~LLC, a Delaware limited liability company~~ (“~~Oxford~~Nasdaq”), asand ~~collateral~~transfer ~~agent~~the ~~and~~listing ~~one~~ of the ~~lenders,~~Common ~~lenders~~Shares ~~listed~~to in the ~~Loan~~OTC-QX ~~Agreement and Lombard Medical Technologies Inc~~Market., aOn ~~Delaware corporation (“LM Technologies”) and Altura Medical~~October 30, ~~Inc.~~2017, athe ~~Delaware~~Company notified ~~corporation~~Nasdaq ~~(“Altura”),~~of ~~both~~its LMintention ~~Technologies~~to ~~and~~voluntarily ~~Altura~~delist ~~are subsidiaries of~~ the Company’s ~~and~~Common ~~the~~Shares ~~“Borrowers”~~from ~~under the Loan Agreement~~Nasdaq. The Company ~~is the~~intends ~~guarantor~~to ~~under~~file ~~the~~a ~~Loan~~Form ~~Agreement. The Amendment~~25, ~~among~~Notification ~~other~~of ~~things,~~Removal ~~(1) changes~~from ~~the~~Listing ~~repayment~~under ~~terms such that starting October~~Section 1,12(b) ~~2017~~of ~~for~~ the ~~periods~~Securities ~~specified~~Exchange inAct ~~the~~of ~~Amendment~~1934, ~~the Borrowers shall make monthly payments of interest~~as ~~only~~amended, ~~and~~with ~~(2) extends~~ the ~~maturity~~SEC ~~date~~on ~~of the loan to April~~November 19, ~~2020~~2017, ifnotifying the ~~Company~~SEC isof ~~unable~~delisting tofrom ~~raise~~Nasdaq ~~additional~~and ~~capital~~trading byon ~~February 1,~~Nasdaq ~~2018,~~will orcease toon ~~September 1, 2020, if~~ the ~~Company~~same ~~is able to raise additional capital by February 1, 2018~~day.

OnThe ~~October 13, 2017 the~~ Company, anticipates LMthat ~~Technologies~~its ~~and~~Common ~~Lombard~~Shares ~~Medical~~will ~~Limited,~~trade aunder ~~subsidiary~~its ofexisting ~~the~~ticker ~~Company~~symbol (“~~LM Limited~~EVAR”), ~~also~~on ~~entered~~the ~~into~~OTC-QX aMarket ~~deed~~effective ~~of confirmation with Oxford,~~ as ~~collateral agent, to confirm that each~~ of the ~~security~~market ~~documents,~~open ~~guarantee~~on ~~and~~November 9, ~~indemnity~~2017. ~~previously provided remain in full force and effect and is a continuing security~~Therefore, ~~guarantee~~ ~~and indemnity (respectively) for~~ the ~~liabilities~~last day of ~~the~~trading on ~~Borrowers~~Nasdaq towill ~~the~~be ~~lenders~~November 8, ~~under the Amendment~~2017.

OnA ~~October 13,~~copy ~~2017~~of ~~LM Technologies,~~the LMpress ~~Limited~~release ~~and~~issued ~~Oxford~~by ~~also~~the ~~entered~~Company ~~into~~is anfurnished IPherewith ~~Security Agreement to provide continuing security for secured liabilities (~~as ~~defined~~Exhibit in99.1 ~~the~~and IPis ~~Security~~incorporated herein ~~Agreement)~~by reference.

On October 13, 2017 the Borrowers also entered into an intellectual property security agreement with Oxford and other lenders listed in the Loan Agreement to grant to Oxford and the lenders security interest in certain collateral listed in the intellectual property security agreement.

On October 13, 2017 the Borrowers also entered into a success fee letter agreement with Oxford providing for payment of an additional fee on the occurrence of certain events, including maturity date of the Loan Agreement, acceleration or prepayment of the loans or a liquidity event (as defined in the success fee letter agreement).

The foregoing descriptions of the Amendment, the deed of confirmation, the IP security agreement, the intellectual property security agreement and the success fee letter do not purport to be complete and are qualified in their entirety by reference to the full text of the Loan Agreement, the deed of confirmation, the IP security agreement, the intellectual property security agreement and the success fee letter, copies of which are filed herewith as Exhibits 10.4, 10.5, 10.6, 10.7 and 10.8, respectively.

Creation of a Direct Financial Obligation

The information set forth above regarding the Amendment is incorporated by reference herein.

Financial Statements and Exhibits

See Exhibit Index

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	~~Lombard Medical, Inc.~~	Lombard Medical, Inc.
Date: October 19, 2017	By:	/s/ Kurt Lemvigh
Date: October 30, 2017		By:	/s/ Kurt Lemvigh
		Kurt Lemvigh
			Kurt Lemvigh Chief Executive Officer
		Chief Executive Officer

[Signature Page to Form 6-K]

EXHIBIT INDEX

Exhibit		Description
10.1		Loan and Security Agreement, dated as of April 24, 2015, by and among Oxford Finance LLC, the lenders party thereto and Lombard Medical Technologies, Inc. (included as Exhibit 4.3 to our Registration Statement on Form F-3 filed on January 13, 2016 and incorporated herein by reference)
99.1		Press Release issued by Lombard Medical, Inc. on October 30, 2017
10.2		Consent and First Amendment to Loan Agreement, dated as of July 30, 2015, by and among Oxford Finance LLC, the lenders party thereto, Lombard Medical Technologies, Inc. and Altura Medical, Inc. (included as Exhibit 4.2 to our Registration Statement on Form F-3 filed on January 13, 2016 and incorporated herein by reference)
10.3		Second Amendment to Loan and Security Agreement, dated as of May 31, 2017, by and among Oxford Finance LLC, the lenders party thereto, Lombard Medical Technologies, Inc. and Altura Medical, Inc.
10.4		Third Amendment to Loan and Security Agreement, dated as of October 13, 2017, by and among Oxford Finance LLC, the lenders party thereto, Lombard Medical Technologies, Inc. and Altura Medical, Inc.
10.5		Deed of Confirmation, dated as of October 13, 2017, by and among Oxford Finance LLC, Lombard Medical Technologies, Inc. and Lombard Medical Limited
10.6		IP Security Agreement, dated as of October 13, 2017, by and among Oxford Finance LLC, Lombard Medical Technologies, Inc. and Altura Medical, Inc.
10.7		Intellectual Property Security Agreement, dated as of October 13, 2017, by and among Oxford Finance LLC, Lombard Medical Technologies, Inc. and Altura Medical, Inc.
10.8		Success Fee Letter, dated as of October 13, 2017, by and among Oxford Finance LLC, Lombard Medical Technologies, Inc. and Altura Medical, Inc.

Filing Compare · Lombard Medical, Inc.